<DOC>
	<DOCNO>NCT00180284</DOCNO>
	<brief_summary>The SITELINE 2 Polyurethane Clinical Investigation analyze safety electrical performance SITELINE 2 Polyurethane pace lead .</brief_summary>
	<brief_title>SITELINE 2 Polyurethane</brief_title>
	<detailed_description>This prospective , single-arm , multi-center U.S. clinical investigation , design demonstrate safety effectiveness SITELINE 2 Polyurethane extendable , retractable pace lead human</detailed_description>
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Patients indicate dual chamber pulse generator implant , pulse generator capable meeting requirement investigational protocol Patients select must study lead initial implant permanent pace lead right atrium right ventricle Age 18 , legal age give inform consent specific state national law Willing capable undergoing device implant participate test associate clinical investigation Available followup approve clinical investigational center , protocoldefined interval A life expectancy 180 day Have likely receive mechanical tricuspid valve course clinical investigation Have surgically uncorrected primary valvular heart disease Have atrial tachyarrhythmia permanent ( i.e. , terminate spontaneously terminate medical intervention ) persistent ( i.e. , terminate medical intervention , terminate spontaneously ) Requiring ICD therapy Have hypersensitivity nominal single dose 1.0 mg ( 0.5 mg per electrode ) dexamethasone acetate drug Enrolled concurrent study , include drug investigation , without Guidant write approval , may confound result study Women pregnant plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Pacemaker lead</keyword>
	<keyword>Electrodes , implantable</keyword>
	<keyword>Cardiac pacing , aritificial</keyword>
</DOC>